NEUROCRINE BIOSCIENCES INC Increase (Decrease) in Other Current Liabilities
NEUROCRINE BIOSCIENCES INC (NBIX) reported Increase (Decrease) in Other Current Liabilities of -$175.00 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2018-11-05
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current liabilities for the quarter ending 2018-09-30 was $0.00.
- NEUROCRINE BIOSCIENCES INC increase (decrease) in other current liabilities for the quarter ending 2017-09-30 was -$60.00K.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month |
|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$175.00K 10-Q · filed 2018-11-05 | |
| 2018-06-30 | -$175.00K 10-Q · filed 2018-07-31 | ||
| 2017-09-30 | -$60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | -$188.00K 10-Q · filed 2018-11-05 | |
| 2017-06-30 | -$128.00K 10-Q · filed 2018-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |